264 related articles for article (PubMed ID: 30107472)
21. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
Hsu JC; Huang YT; Lin LY
Aging (Albany NY); 2020 Nov; 12(23):24219-24227. PubMed ID: 33226371
[TBL] [Abstract][Full Text] [Related]
22. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis.
Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Liao JN; Chen TJ; Lip GY; Chen SA
Heart Rhythm; 2014 Oct; 11(10):1752-9. PubMed ID: 24952148
[TBL] [Abstract][Full Text] [Related]
23. Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhythmic drug medication.
Brembilla-Perrot B; Girerd N; Sellal JM; Olivier A; Manenti V; Villemin T; Beurrier D; DE Chillou C; Louis P; Selton O; DE LA Chaise AT
J Cardiovasc Electrophysiol; 2014 Aug; 25(8):813-820. PubMed ID: 24654647
[TBL] [Abstract][Full Text] [Related]
24. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
[TBL] [Abstract][Full Text] [Related]
25. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
27. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.
Allan V; Banerjee A; Shah AD; Patel R; Denaxas S; Casas JP; Hemingway H
Heart; 2017 Feb; 103(3):210-218. PubMed ID: 27580623
[TBL] [Abstract][Full Text] [Related]
28. Factors Influencing Oral Anticoagulation Prescription for Patients Presenting to Emergency Departments With Atrial Fibrillation and Flutter.
Miller RJH; Chew DS; Rezazadeh S; Klassen S; Pournazari P; Lang E; Quinn FR
Can J Cardiol; 2018 Jun; 34(6):804-807. PubMed ID: 29801744
[TBL] [Abstract][Full Text] [Related]
29. First Diagnosis of Atrial Fibrillation at the Time of Stroke.
Borowsky LH; Regan S; Chang Y; Ayres A; Greenberg SM; Singer DE
Cerebrovasc Dis; 2017; 43(3-4):192-199. PubMed ID: 28208140
[TBL] [Abstract][Full Text] [Related]
30. Typical atrial flutter but not fibrillation predicts coronary artery disease in formerly healthy patients.
Iden L; Richardt G; Weinert R; Groschke S; Toelg R; Borlich M
Europace; 2021 Aug; 23(8):1227-1236. PubMed ID: 33611584
[TBL] [Abstract][Full Text] [Related]
31. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database.
van den Ham HA; Klungel OH; Singer DE; Leufkens HG; van Staa TP
J Am Coll Cardiol; 2015 Oct; 66(17):1851-9. PubMed ID: 26493655
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and outcome of lone atrial fibrillation at a tertiary referral centre: the Groote Schuur Hospital experience.
Thomas V; Schulein S; Millar RN; Mayosi BM
Cardiovasc J Afr; 2018; 29(5):268-272. PubMed ID: 30395140
[TBL] [Abstract][Full Text] [Related]
33. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
35. Thromboembolism and bleeding in patients with atrial fibrillation and liver disease - A nationwide register-based cohort study: Thromboembolism and bleeding in liver disease.
Steensig K; Pareek M; Krarup AL; Sogaard P; Maeng M; Tayal B; Lee CJ; Torp-Pedersen C; Lip GY; Holland-Fischer P; Kragholm KH
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101952. PubMed ID: 35609823
[TBL] [Abstract][Full Text] [Related]
36. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB; Torp-Pedersen C; Hansen ML; Lip GY
Thromb Haemost; 2012 Jun; 107(6):1172-9. PubMed ID: 22473219
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Adherence to Guideline-Directed Antithrombotic Therapy for Atrial Fibrillation at Hospital Discharge.
Dupree L; DeLosSantos M; Smotherman C
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):502-508. PubMed ID: 29806486
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of CHA
van Doorn S; Rutten FH; O'Flynn CM; Oudega R; Hoes AW; Moons KGM; Geersing GJ
Int J Cardiol; 2018 Dec; 273():123-129. PubMed ID: 30224261
[TBL] [Abstract][Full Text] [Related]
39. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study.
Paciaroni M; Agnelli G; Falocci N; Caso V; Becattini C; Marcheselli S; Rueckert C; Pezzini A; Poli L; Padovani A; Csiba L; Szabó L; Sohn SI; Tassinari T; Abdul-Rahim AH; Michel P; Cordier M; Vanacker P; Remillard S; Alberti A; Venti M; Scoditti U; Denti L; Orlandi G; Chiti A; Gialdini G; Bovi P; Carletti M; Rigatelli A; Putaala J; Tatlisumak T; Masotti L; Lorenzini G; Tassi R; Guideri F; Martini G; Tsivgoulis G; Vadikolias K; Liantinioti C; Corea F; Del Sette M; Ageno W; De Lodovici ML; Bono G; Baldi A; D'Anna S; Sacco S; Carolei A; Tiseo C; Acciarresi M; D'Amore C; Imberti D; Zabzuni D; Doronin B; Volodina V; Consoli D; Galati F; Pieroni A; Toni D; Monaco S; Baronello MM; Barlinn K; Pallesen LP; Kepplinger J; Bodechtel U; Gerber J; Deleu D; Melikyan G; Ibrahim F; Akhtar N; Mosconi MG; Bubba V; Silvestri I; Lees KR
Stroke; 2015 Aug; 46(8):2175-82. PubMed ID: 26130094
[TBL] [Abstract][Full Text] [Related]
40. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
